The study evaluated the effect of carvedilol on survival in patients with severe chronic heart failure. A total of 2289 patients with symptoms at rest or minimal exertion, euvolemic status, and an ejection fraction of less than 25 percent were randomly assigned to receive either carvedilol or placebo. The mean follow-up period was 10.4 months. The results showed that carvedilol reduced the risk of death by 35 percent and the risk of death or hospitalization by 24 percent compared to placebo. These benefits were consistent across various subgroups, including age, sex, left ventricular ejection fraction, cause of heart failure, and history of recent hospitalization. Carvedilol was well-tolerated, with fewer patients discontinuing treatment due to adverse effects. The study concluded that carvedilol provides substantial benefits in patients with severe chronic heart failure, regardless of their baseline characteristics.The study evaluated the effect of carvedilol on survival in patients with severe chronic heart failure. A total of 2289 patients with symptoms at rest or minimal exertion, euvolemic status, and an ejection fraction of less than 25 percent were randomly assigned to receive either carvedilol or placebo. The mean follow-up period was 10.4 months. The results showed that carvedilol reduced the risk of death by 35 percent and the risk of death or hospitalization by 24 percent compared to placebo. These benefits were consistent across various subgroups, including age, sex, left ventricular ejection fraction, cause of heart failure, and history of recent hospitalization. Carvedilol was well-tolerated, with fewer patients discontinuing treatment due to adverse effects. The study concluded that carvedilol provides substantial benefits in patients with severe chronic heart failure, regardless of their baseline characteristics.